Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Medical University of Vienna
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01356290CT.gov Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors | — | Recruiting | — | — | — |
NCT00112502CT.gov Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme | — | Completed | — | — | — |
NCT00047281CT.gov Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma | — | Completed | — | — | — |
NCT00068770CT.gov Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT | — | Terminated | — | — | — |
NCT00047294CT.gov Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Central Nervous System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Celecoxib (this asset) | Medical University of Vienna | P2 | B · 62 |
| Procarbazine | Universitätsmedizin Mannheim | P3 | BBB |
| Vincristine Sulfate | Northwestern University | P3 | BBB |
| Irinotecan | EpicentRx, Inc. | P2 | BBB |
| Etoposide | NewLink Genetics Corporation | P3 | BBB |
| Gefitinib | Memorial Sloan Kettering Cancer Center | P2 | BBB |
| Camustine | Lisata Therapeutics, Inc. | P3 | BBB |
| Nivestim | St. Jude Children's Research Hospital | P3 | BBB |
| Carboplatin | OHSU Knight Cancer Institute | P3 | BBB |
+42 more in the Central Nervous System Neoplasm cohort
Other indications for Celecoxib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis, Hip | — | P4 | BB · 71 |
| Osteoarthritis, Knee | — | P4 | BB · 69 |
| Bipolar Depression | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Celecoxib in Central Nervous System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/celecoxib-central-nervous-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →